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Abstract
Locked nucleic acid is an RNA derivative in which the ribose
ring is constrained by a methylene linkage between the 2P-oxygen
and the 4P-carbon. This conformation restriction increases binding
affinity for complementarity sequences and provides an exciting
new chemical approach for the control of gene expression and
optimization of microarrays. ß 2001 Elsevier Science Ltd. All
rights reserved.
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1. Introduction
In 1978, Zamecnik and Stephenson [1] ¢rst focused wide
attention on the potential of oligonucleotides as powerful
tools for controlling gene expression. Since then, DNA
and RNA analogs containing diverse chemical features
have been developed in attempts to improve potency, spe-
ci¢city and therapeutic e⁄cacy (Fig. 1). One of these ana-
logs, phosphorothioate DNA, has provided the ¢rst ap-
proved oligonucleotide drug, Fomivirsen [2], and 2P-O-
alkyl RNA^DNA chimera are being used in several on-
going clinical trials [3]. Oligonucleotides are also e¡ective
tools for functional genomics, and ISIS Pharmaceutical
has developed high-throughput screening assays to rapidly
identify oligonucleotides that can reduce the expression of
biologically important genes and validate novel therapeu-
tic targets (http://www.isip.com).
In spite of this progress, the successful application of
oligonucleotides depends on a number of factors (Table
1) and it has recently been estimated that up to 90% of
published work using oligonucleotides to inhibit gene ex-
pression may be at least partially unreliable [4]. Because
oligonucleotides are not yet a routine tool for chemical
genetics, attention continues to be focused on the develop-
ment of additional oligonucleotide analogs [5]. The use of
oligonucleotides as research tools and diagnostic agents is
so pervasive that even modest improvements in their prop-
erties are likely to have a large impact. Not only would
improved oligomers be more e¡ective antisense agents,
they would also provide new options for diagnostic tests,
enhanced probes for basic research, and tools for gene
array analysis that provide better sensitivity. Examples
of promising analogs include, peptide nucleic acid (PNA)
[6], phosphoramidate DNA [7], hexitol nucleic acid (HNA)
[8] and morpholino [9] oligomers (Fig. 1, Table 2). This
minireview will describe the properties of one new analog,
locked nucleic acid (LNA), that may possess important
advantages for the recognition of complementary sequen-
ces.
2. LNA
In 1998, the Wengel [10,11] and Imanishi [12] laborato-
ries described oligomer synthesis and hybridization using a
novel nucleotide termed LNA (Fig. 1), with a subsequent
report from the Wang laboratory appearing in 1999 [13].
LNA nucleotides contain a methylene bridge that connects
the 2P-oxygen of ribose with the 4P-carbon. This bridge
results in a locked 3P-endo conformation, reducing the
conformational £exibility of the ribose and increasing
the local organization of the phosphate backbone.
LNA bases are linked by the same phosphate backbone
found in DNA or RNA, allowing LNA oligomers to be
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obtained using standard reagents and automated synthe-
sizers. The use of standard reagents and synthesizers
avoids the need to develop new protocols and is an im-
portant practical advantage. The similarity of LNA to
DNA/RNA synthesis also permits LNA bases to be inter-
spersed among DNA and RNA, permitting the properties
of LNA-containing oligomers to be ¢ne-tuned. For exam-
ple, as discussed below, the ability to mix DNA and RNA
bases allows the a⁄nity for complementary sequences or
the susceptibility to RNase H to be optimized for individ-
ual applications. Another practical advantage is that
LNAs are as soluble as DNA or RNA, facilitating their
handling and simplifying experiments. Finally, because
LNAs possess a charged phosphate backbone they can
be delivered into cells using standard protocols that em-
ploy cationic lipid.
Several protocols for the synthesis of LNA monomers
have been published [10^14]. LNA monomers are not yet
commercially available, but the custom synthesis of LNAs
is o¡ered by Proligo (Boulder, CO, USA, http://www.pro-
ligo.com). Prices for commercial LNA synthesis are high,
but it is expected that they will fall as the demand for
LNAs increases. Availability of custom synthesis sets
LNA apart from other oligonucleotides with altered sugar
backbones [5], such as pentopyranosyl [15] or HNA [8]
oligomers that also bind with high a⁄nity but that are
not generally available.
3. Structures of LNA hybrids
Nuclear magnetic resonance has been used to determine
solution structures of LNA^DNA chimeras bound to
DNA [16] or RNA [17]. Both the RNA and DNA hybrids
form right-handed helices containing normal Watson^
Crick pairs with all the bases in the anti conformation.
The LNA bases within the DNA^LNA strand of the
RNA complex induce £anking DNA bases to adopt an
A type conformation. This is an important observation
because the ability of LNA bases to a¡ect the conforma-
tion of the DNA strand will a¡ect its ability to activate
RNase H cleavage of bound RNA, an important consid-
eration for antisense applications (see below). Both struc-
tures also suggest that enhanced stability of LNA is due to
local organization of the phosphate backbone which in-
creases the strength of base stacking interactions.
Fig. 1. Nucleic acid analogs studied for their potential as antisense agents. Phosphodiester DNA, phosphorothioate DNA, PNA, phosphoramidate
DNA, morpholino and LNA.
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4. A⁄nity of LNAs for complementary sequences
Several studies have been published that demonstrate
that LNAs have improved a⁄nities for complementary
DNA and RNA sequences (Table 3) (Fig. 2). Melting
temperatures (Tms) have been increased by as much as
41‡C relative to DNA:DNA complexes of the same length
and sequence, and addition of a single LNA base can raise
the Tm value by as much as 9.6‡C. As more LNA bases
are incorporated, the increase per LNA base declines. In
some LNA^DNA chimeras the inclusion of LNA bases
changes the Tm values by less than 2‡C per base. Longer
oligomers that would have high Tm values regardless of
the presence of LNA also show smaller e¡ects when LNA
bases are included. Taken together, these data indicate
that inclusion of LNA bases will have the greatest e¡ect
on oligomers less than 10 bases long. Short all-LNA olig-
omers combine high a⁄nity binding with minimal size.
We have observed that LNA binding is sensitive to the
presence of mismatched bases (Braasch, unpublished re-
sults). However, because LNA o¡ers the potential to ob-
tain oligomers that bind with exceptionally high a⁄nity,
the design of mismatch-containing oligomers will need to
be carefully considered to ensure adequate discrimination
between fully complementary and mismatch-containing
LNAs. Homopyrimidine LNAs can also bind to duplex
DNA by triple helix formation [18,19]. This triplex forma-
tion occurs at neutral pH [19] and suggests that LNA may
Table 1
Factors a¡ecting the utility of DNA/RNA analogs and mimics
Factor Comments
RNase H activity Catalytic destruction of mRNA ampli¢es e⁄cacy.
Oligomers can be targeted through mRNA.
A⁄nity for target
sequence
High a⁄nity is necessary for e⁄cient binding under
physiologic conditions and may lead to more
e⁄cient gene arrays.
Clinical use Any application aimed at therapy will bene¢t from
prior clinical experience with oligomers that possess
the same chemical features.
Nuclease resistance The oligomer must be stable inside the cell.
Commercial avail-
ability
Necessary for wide use.
Standard synthetic
procedures
Synthetic procedures adapted from DNA or
peptide synthesis are familiar to many researchers
and allow oligomers to be readily obtained.
Solubility Some oligonucleotide analogs, particularly those
that are uncharged, are less soluble than others.
Methods for
cellular delivery
The use of cationic lipid is a standard procedure,
although other methods are available. Oligomers
containing phosphorothioate linkages are
spontaneously taken up by some animal and
human tissues.
Binding to
cellular proteins
A major cause of nonspeci¢c e¡ects, but also a
contributor to favorable pharmacokinetics.
Phosphorothioate linkages contribute to protein
binding, as does the potential to form secondary
structure such as Q-quartets.
Toxicity Low toxicity in clinical trials to date. Toxicity in
cell culture can be unpredictable and sequence-
dependent. Proper controls are a necessity.
Ability to act as
a primer
Necessary for applications involving polymerase
chain reaction, sequencing.
Table 2
Properties of chemically modi¢ed oligomers
Oligomer chemistry RNase H activity Elevated a⁄nity Clinical use Nuclease resistant Commercially available
PO-DNA yes no no no yes
PO-RNA no no no no yes
PS-DNA yes no yes yes yes
2P-O-MeRNA no yes no yes yes
2P-O-MOE-RNA no yes no yes no
2P-O-MeRNA/DNA yes yes yes yes yes
2P-O-MOE-RNA/DNA yes yes yes yes no
PNA no yes no yes yes
Phosphoramidate no yes no yes yes
Morpholino no yes no yes yes
LNA yesa yes no yes yes
PO = phosphodiester; PS = phosphorothioate; Me = methyl ; MOE = methoxyethoxy; PNA = peptide nucleic acid; LNA = locked nucleic acid.
aEspecially as LNA^DNA chimera.
Fig. 2. LNAs bind tightly to DNA. Melting curves for an LNA oligo-
nucleotide bound to complementary DNA compared with the melting
curve for the analogous all-DNA duplex. The sequence of the LNA is
5P-AGGATCmeTAGG-3P (Braasch, unpublished results).
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o¡er advantages for recognition of duplex DNA within
cells.
5. RNase H activation by LNAs and LNA^DNA chimera
RNase H is an enzyme that normally cleaves the RNA
strand of RNA^DNA hybrids formed during lagging
strand synthesis. DNA oligonucleotides can bind mRNA
and activate RNase H, causing the target mRNA to be
degraded [20] (Fig. 3). This is a critical determinant for the
e⁄cacy of antisense oligonucleotides because the DNA is
then free to bind additional mRNAs, amplifying its ability
to inhibit gene expression. Oligomers that cannot activate
RNase H, such as PNA [6,21,22] or 2P-O-alkyl RNA
[23,24] can also act as antisense agents, but are most active
when targeted to the terminal sequence of the 5P-untrans-
lated region where they can block binding of the trans-
lation apparatus (Fig. 3). Oligomers that cannot activate
RNase H are less active when targeted elsewhere within
mRNA because they can be displaced by the ribosome as
it carries out translation, but are useful for applications
such as altering splicing [25] or inhibiting ribonucleopro-
teins such as telomerase [26] where they are less readily
displaced.
Wengel et al. have found that oligonucleotides contain-
ing only LNA bases form hybrids with RNA that activate
RNase H less well than do corresponding DNA oligonu-
cleotides [27]. Taking advantage of the standard synthesis
of DNA and LNA to obtain DNA^LNA chimera, Wengel
et al. have observed that these chimeric oligonucleotides
readily activate RNase H. The LNA bases confer en-
hanced binding, while DNA bases create a suitable
RNA^DNA hybrid to act as a substrate for RNase H.
These results demonstrate that LNAs are £exible reagents
and that RNase H activation can be exploited or avoided
depending on the demands of given experimental strategies
and targets. It is possible that LNAs may be able to bind
throughout mRNA and function e¡ectively as antisense
agents by virtue of their exceptionally tight a⁄nities for
complementary RNA sequences, but this outcome has not
yet been experimentally demonstrated.
Table 3
Melting temperature (Tm) values for LNA and LNA/DNA
LNA or LNA/DNA Tm Tm(ref) vTm vTm/LNA base Refs.
GTGATATGC 44 28 16 5.3 [10]
GTGAUATGC 44 [10]
GTGAGATGC 49 33 15 5 [10]
GTGACATGC 52 [10]
GTGAAATGC 45 [10]
GTGATATGmeC 64 28 36 4.5 [10]
GGTGGTTTGTTTG 57 47 10 2.5 [10]
GGTGGTTTGTTTG 83 47 36 3 [10]
GCGTTTTTTGCT 50 47 3 3 [12]
GCGTTTTTTGCT 51 47 4 2 [12]
GCGTTTTTTGCT 58 47 11 1.8 [12]
TCTCTCTCCCTTTT 54 46 8 1.1 [12]
TCTCTCTCCCTTTT 65 46 19 3.2 [12]
TCTCTCTCCCTTTT 74 46 28 2.2 [12]
CmeCmeTCmeGCmeCmeT 80 44 36 2.5 [29]
CmeCmeTTGCmeCmeT 71 36 35 2.45 [29]
AGGCmeAAGG 77 36 41 5 [29]
GTGTTTTGC 52 28 24 5 [28]
GTGTCCGAGACGTTG 72 59 13 1.5 [27]
GTGTCCGAGACGTTG 83 59 24 3 [27]
GTGTCCGAGACGTTG s 90 59 s 31 2 [27]
CACTATACG 40 29 11 3.3 [30]
CTGATATGC 36.8 27.2 9.6 9.6 [17]
CTGATATGC 51.6 27.2 24.4 8.1 [17]
ATCTCTCCGCTTCCTTTC 65 58 7 0.8 [13]
AGGGTCGCTCmeGGTGT s 96 53 43 3 [*]
AGGGTCGCTCmeAATGT 83 [*]
CmeAGTTAGGGTTAG 81 50 31 3.1 [*]
CmeAGTTAGAATTAG 65 [*]
TAGGGT 56 nd - - [*]
TAGGGTTA 74 22 52 6.5 [*]
AGGATCmeTAGGTGAA s 96 71 25 2.9 [*]
AGGATCmeTAGG 73 39 34 3.4 [*]
AGGATCmeTAGGTGAA 59 53 6 0.6 [*]
Reference Tm values are for analogous DNA oligonucleotides. Boldface bases are LNA. Cme = 5-methylcytosine. All oligomers are shown from 5P to
3P. nd: melting temperature not detected. [*] : Dwaine Braasch, unpublished results.
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6. Stability of LNAs to cleavage by nucleases
To be e¡ective inside cells or in cell extract antisense
oligomers must be stable towards digestion by nucleases.
Wengel et al. have reported that oligomers that contain
mixtures of LNA and DNA bases are much more resistant
to degradation in rat blood serum than the analogous
DNA oligonucleotide [27]. The degree of nuclease resis-
tance varies depending on the location of DNA and
LNA bases, with placement of LNA bases at the 3P to
5P termini being an e¡ective strategy to lessen hydrolysis
by exonucleases. As with a⁄nity and RNase H activation,
it is likely that nuclease sensitivity can be ¢ne-tuned by
judicious placement of LNA and DNA bases. Another
standard approach to improving stability of antisense
DNA and RNA oligomers is to incorporate phosphoro-
thioate linkages. Wengel et al. have shown that this is
possible and that the resulting phosphorothioate LNAs
were able to recognize complementary sequences with af-
¢nities comparable to analogous phosphodiester LNAs
[28]. Use of phosphorothioate linkages can reduce the tar-
get selectivity of oligonucleotides by increasing binding to
proteins, but this enhanced binding also improves pharma-
cokinetic properties and may be a prerequisite for success-
ful use of LNAs to inhibit gene expression in animals.
7. LNA and PNA
Like LNA, PNA [6] is another emerging DNA/RNA
mimic and comparison of LNA and PNA is a useful ex-
ercise for putting the properties of LNA into perspective
(Fig. 4). LNA and PNA both bind with high a⁄nities to
complementary sequences, although the limited set of
comparisons that we have performed indicates that bind-
ing by LNAs is often even stronger than that of analogous
PNAs (D. Braasch, unpublished results). Both are com-
mercially available and both cannot activate RNase H.
There are also important di¡erences. PNAs are un-
charged, whereas LNA has a normal phosphate backbone.
Because the LNA backbone is charged, we do not expect
that LNAs will have the remarkable strand invasion prop-
erties displayed by PNAs, although additional research
will be necessary before a ¢nal determination of the strand
invasion properties of can be made. Their uncharged back-
bone also lowers the solubility of PNAs, and while this is
Fig. 3. Mechanisms for inhibition of gene. (A) Inhibition of gene expression by an antisense oligonucleotide that binds to the 5P-untranslated region
and blocks binding of the translation apparatus. (B) Promotion of RNA cleavage and inhibition of gene expression by an antisense oligonucleotide that
can activate RNase H.
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not a large obstacle for researchers with experience han-
dling PNA, the ready solubility of LNA will be a useful
feature for new users.
Another critical distinction between LNA and PNA is
that PNAs are assembled using standard peptide synthesis
protocols, so it is easier to append peptide motifs onto
PNAs than onto LNAs. Conversely, LNAs are assembled
using standard DNA synthesis techniques, so it will be
easier to make LNA^DNA hybrids that possess tailored
binding a⁄nities and the ability to activate RNase H. It
will also be possible to use LNA bases to optimize existing
antisense oligonucleotides, potentially leading to the im-
mediate development of a wide range of improved com-
pounds, including ones already in clinical development.
Thus, while PNA and LNA share some similarities, there
are also important di¡erences. It is likely that PNAs will
be preferred for some applications, while LNAs will be
preferred for others.
8. Applications of LNAs
Given that the ¢rst description of LNA was in 1998 it is
not surprising that there have been relatively few pub-
lished applications. A hint of the promise of LNAs as
antisense agents is the observation by Wengel et al. that
LNA^DNA chimera targeted to DOR, a G-protein
coupled receptor, produce a physiologic response in mice
when injected directly into the brain [27]. Injections of
LNA were well tolerated by the mice, suggesting that their
in vivo toxicity will be mild.
The high a⁄nity of hybridization demonstrated by pure
LNA oligomers may allow improvement of DNA array
technology and DNA diagnostics. Not only do LNAs of-
fer the potential for high a⁄nity binding, but the fact that
their synthesis and physical properties closely resemble
those for DNA means that existing protocols for creating
arrays will need only minimal adjustment. In the only
study reported to date, Orum et al. have immobilized
LNAs complementary to the Factor V Leiden mutation
to individual wells of a microtiter plate [29]. They then
developed a 1-h enzyme-linked immunosorbent-type assay
capable of discriminating between ampli¢ed DNA from
Factor V homozygotes, heterozygotes and una¡ected in-
dividuals.
9. Conclusion
The initial results on the properties and applications of
LNAs make it clear that LNAs possess extraordinarily
high a⁄nities for complementary sequences and forcefully
suggest that LNAs have the potential to be improved
agents for oligonucleotide arrays and in vivo repression
Fig. 4. Comparison of the properties of LNA and PNA.
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of gene expression. Advantages include low toxicity, the
ability to make LNA^DNA chimeras, nuclease resistance,
synthesis by standard methods, and availability from a
commercial supplier. These advantages, combined with
the favorable data generated since the discovery of
LNA, suggest that LNA will be a valuable addition to
the chemical tool kit available for nucleic acid recognition
and chemical genetics.
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